News

Shivaji Dasgupta, an autonomous Brand Consultant, writes that India’s obsession with shortcuts risks turning a breakthrough ...
Lilly announced mixed earnings results on May 1. It missed first-quarter estimates for earnings but beat the same for sales. Sales of key drugs, Mounjaro, Zepbound, Jardiance, and Taltz beat ...
One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...
Around 180,000 people with type 2 diabetes in the UK could be in line for treatment with Eli Lilly's Mounjaro after the drug was recommended for NHS use by cost-effectiveness overseer NICE.
Lilly’s tirzepatide is already approved for weight management under the brand name Zepbound in the US and as Mounjaro in some other countries, including the UK, while semaglutide is approved for ...
Its rival drug Zepbound now has the lead in obesity prescriptions, and Lilly’s diabetes version of the drug, Mounjaro, is on track to catch up with Ozempic as well by next August, according to ...
EXCLUSIVE: UTA has signed award-winning actress, producer, and New York Times bestselling author Lilly Singh for representation in all areas, with an eye toward helping her to secure new ...
PLEASE TAKE A LOOK AT YOUR SCREEN IF YOU CAN. THIS IS LILY ANSAH, MILWAUKEE POLICE SAY WAS LAST SEEN TUESDAY NIGHT AROUND 5:00 NEAR 19TH AND CAPITOL DRIVE IN THE CITY’S RUFUS KING NEIGHBORHOOD.
Eli Lilly and Company discovers ... and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including ...
Happy to have Lilly here on this final day of the conference ... versus what could unfold in the rest of the world. So Q1 Mounjaro, and Mounjaro, you have the same brand. Yes.
Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for certain consumers, many are still turned off by the meds’ sticker shock.